Morgan Lewis represented Cyclerion Therapeutics in the transaction. Cyclerion Therapeutics Inc. closed a licensing agreement with Akebia Therapeutics Inc. for the development and commercialization of praliciguat,...
This content is for Standard 1 Year members only. LoginJoin Now